

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 63

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/ERC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 63

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/ERC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 63

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/ERC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

**acidum obeticholicum**

obeticholic acid

6 $\alpha$ -ethyl-3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid


acide obéticholique

acide 6 $\alpha$ -éthyl-3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oïque

ácido obeticólico

ácido 6 $\alpha$ -etil-3 $\alpha$ ,7 $\alpha$ -dihidroxi-5 $\beta$ -colan-24-oico

C<sub>26</sub>H<sub>44</sub>O<sub>4</sub>



**acidum tiomolibdicum**

tiomolibdic acid

dihydrogen(tetrasulfidomolybdate)


acide tiomolibdique

tétrasulfidomolybdate d'hydrogène

ácido tiomolibdico

dihidrógeno(tetrasulfuomolibdato)

H<sub>2</sub>MoS<sub>4</sub>



**afacifenacinum**

afacifenacin



(4S)-4-phenyl-3-(1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one

afacifénacine

(4S)-4-phényl-3-(1-[[3-(trifluorométhoxy)phényl]méthyl]pipéridin-4-yl)-3,4-dihydroquinazolin-2(1H)-one

afacifenacina

(4S)-4-fenil-3-(1-[[3-(trifluorometoxi)fenil]metil]piperidin-4-il)-3,4-dihidroquinazolin-2(1H)-ona

**afegostat**



afegostat

(3*R*,4*R*,5*R*)-5-(hydroxymethyl)piperidine-3,4-diol

afégostat

(3*R*,4*R*,5*R*)-5-(hydroxyméthyl)pipéridine-3,4-diol

afegostat

(3*R*,4*R*,5*R*)-5-(hidroximetil)piperidina-3,4-diol**aganirsenum**

aganirsenum

*all-P-ambo*-thymidylyl-(3' → 5')-2'-deoxy-*P*-thioadenylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thiocytydyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiadenylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiadenylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thioadenylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidine

aganirsenum

*tout-P-ambo-P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioadénylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioadénylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioadénylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-thymidine

aganirsén

*todo-P-ambo-timidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidina*

 $C_{242}H_{307}N_{91}O_{127}P_{24}S_{24}$ 

(3'-5')d(P-thio)(T-A-T-C-C-G-G-A-G-G-G-C-T-C-G-C-C-A-T-G-C-T-G-C-T)

**albitiazolii bromidum**  
albitiazolium bromide


3,3'-(dodecan-1,12-diyl)bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium] dibromide

bromure d'albitiazolium

dibromure de 3,3'-(dodécane-1,12-diyl)bis[5-(2-hydroxyéthyl)-4-méthyl-1,3-thiazol-3-ium]

bromuro de albitiazolio

dibromuro de 3,3'-(dodecan-1,12-diil)bis[5-(2-hidroxietil)-4-metil-1,3-tiazol-3-io]

 $C_{24}H_{42}Br_2N_2O_2S_2$ 


**arhalofenatum**  
arhalofenate


2-(acetamido)ethyl (2*R*)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate

arhalofénate

(2*R*)-2-(4-chlorophényl)-2-[3-(trifluorométhy)phénoxy]acétate de 2-(acétylamino)éthyle

arhalofenato

(2*R*)-2-(4-clorofenil)-2-[3-(trifluorometil)fenoxi]acetato de 2-(acetamido)etilo

 $C_{19}H_{17}ClF_3NO_4$ 


**atalurenium**

ataluren


3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

ataluren

acide 3-[5-(2-fluorophényl)-1,2,4-oxadiazol-3-yl]benzoïque

atalureno

ácido 3-[5-(2-fluorofenil)-1,2,4-oxadiazol-3-il]benzoico

C<sub>15</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>3</sub>**atiratecanum**


atiratecan

(9*S*)-9-ethyl-10,13-dioxo-1-pentyl-9,10,13,15-tetrahydro-1*H*,12*H*-pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-*de*]quinazolin-9-yl glycyl-*N*-methylglycinate

atiratécán

glycyl-*N*-méthylglycinate de (9*S*)-9-éthyl-10,13-dioxo-1-pentyl-9,10,13,15-tétrahydro-1*H*,12*H*-pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-*de*]quinazolin-9-yle

atiratecán

glicil-*N*-metilglicinato de (9*S*)-9-etil-10,13-dioxo-1-pentil-9,10,13,15-tetrahydro-1*H*,12*H*-pirano[3'',4'':6',7']indolizino[2',1':5,6]pirido[4,3,2-*de*]quinazolin-9-iloC<sub>31</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>**bardoxolonum**

bardoxolone


2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid

bardoxolone

acide 2-cyano-3,12-dioxooléana-1,9(11)-dién-28-oïque

bardoxolona

ácido 2-ciano-3,12-dioxooleana-1,9(11)-dien-28-oico

C<sub>31</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>

**beclanorsenum**

beclanorsen


*all-P-ambo-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-O,4'-C-methylene-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine*

béclanorsen

*tout-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-déoxyadénosine*

beclanorsén

*todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-O,4'-C-metileno-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxiadenosina*

C<sub>159</sub>H<sub>201</sub>N<sub>58</sub>O<sub>82</sub>P<sub>15</sub>S<sub>15</sub>(3'-5')d(P-thio)(mrC-rT-C-C-C-A-A-C-G-T-G-C-G-mrC-mrC-A)**bixalomerum**

bixalomer



cross linked polymer made of *N,N,N',N'*-tetrakis(3-aminopropyl)butane-1,4-diamine *N* substituted by bivalent substituent groups 2-hydroxypropane-1,2-diyl and 1-(hydroxymethyl)ethylene ( $x=20$ ,  $45 \leq y \leq 50$ )

bixalomère

*N,N,N',N'*-tétrakis(3-aminopropyl)butane-1,4-diamine *N* substituée par les groupes substituants divalents 2-hydroxypropane-1,2-diyle et 1-(hydroxyméthyl)éthylène pour former un polymère réticulé ( $x=20$ ,  $45 \leq y \leq 50$ )

bixalómero

*N,N,N',N'*-tétrakis(3-aminopropil)butano-1,4-diamina *N* sustituida por los grupos sustituyentes divalentes 2-hidroxipropano-1,2-diilo y 1-(hidroximetil)etileno para formar un polímero reticulado ( $x=20$ ,  $45 \leq y \leq 50$ )



**briakinumabum #**  
briakinumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* interleukin 12 beta subunit (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; (224-224":227-227")-bisdisulfide dimer

briakinumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* interleukine 12 sous-unité bêta (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfure avec la chaîne légère kappa (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; dimère (224-224":227-227")-bisdisulfure

briakinumab

inmunoglobulina G1-lambda, anti-[interleukina 12 subunidad beta (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfuro con la cadena ligera kappa (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; dimer (224-224":227-227")-bisdisulfuro

C<sub>6376</sub>H<sub>9874</sub>N<sub>1722</sub>O<sub>1992</sub>S<sub>44</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAF 50  
 IRYDGSNKYY ADSVKGRTI SRDNSKNTLY LQMNSLRAED TAVYCKTHG 100  
 SHDNWQQTMT VVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150  
 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTPVSSS LGTQTYICNV 200  
 NHKPSNTKVD KKVEPKSCDK THTCPAPAP ELLGGPSVFL FPPKPKDTLM 250  
 ISRTPEVTCV VVDVSHEDPE VKNWYVDGV EVHNAKTKPR EEQYNSTYRV 300  
 VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTL 350  
 PSREEMTKNQ VSLTCLVKG F YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400  
 SFFLYSKLTV DKSRWQQGNV FSCVMHEAL HNHYTQKSL S LSPGK 445

## Light chain / Chaîne légère / Cadena ligera

QSVLTQPPSV SGAPGQRVTI SCGSRSNIG SNTVKWYQQL PGTAPKLLIY 50  
 YNDQRFSGVP DRFSGSKSGT SASLAITGLQ AEDEADYCCQ SYDRYTHPAL 100  
 LFGTGTKVTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150  
 VAWKADSSPV KAGVETTPPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200  
 THEGSTVEKT VAPTECS 217

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 142-198 259-319 365-423  
 22"-96" 142"-198" 259"-319" 365"-423"

Intra-L 22"-89" 139"-198"  
 22"-89" 139"-198"

Inter-H-L 218-216' 218"-216"  
 Inter-H-H 224-224" 227-227"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

295, 295"

**budiodaronum**

budiodarone


(2S)-butan-2-yl 2-(3-{4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl}-1-benzofuran-2-yl)acetate

budiodarone

2-(3-{4-[2-(diéthylamino)éthoxy]-3,5-diiodobenzoyl}-1-benzofuran-2-yl)acétate de (2S)-butan-2-yl

budiodarona

2-(3-{4-[2-(diethylamino)etoxi]-3,5-diiodobenzoiil}-1-benzofuran-2-il)acetato de (2S)-butan-2-ilo

C<sub>27</sub>H<sub>31</sub>I<sub>2</sub>NO<sub>5</sub>**burapitantum**

burapitant

2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}piperidin-4-yl)-2-methylpropanamide



burapitant

2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorométhyil)phényl]acétyl}-2-(3,4-dichlorophényl)morpholin-2-yl]éthyl}pipéridin-4-yl)-2-méthylpropanamide

burapitant

2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorometil)fenil]acetil}-2-(3,4-diclorofenil)morfolin-2-il]etil}piperidin-4-il)-2-metilpropanamida



**danegaptidum**



danegaptide

(2*S*,4*R*)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid

danégaptide

acide (2*S*,4*R*)-1-(2-aminoacétyl)-4-benzamidopyrrolidine-2-carboxylique

danegaptida

ácido (2*S*,4*R*)-1-(2-aminoacetil)-4-benzamidopirrolidina-2-carboxílico**daratumumabum #**

daratumumab


immunoglobulin G1-kappa, anti-[*Homo sapiens* ADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], *Homo sapiens* monoclonal antibody;  
 gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; (231-231'':234-234'')-bisdisulfide dimer

daratumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

daratumumab

inmunoglobulina G1-kappa, anti-[ADP-ribosil ciclase 1 de *Homo sapiens* (CD38, hidrolasa 1 de ADP ciclico-ribosa, cADPr hidrolasa 1, T10)], anticuerpo monoclonal de *Homo sapiens*;  
 cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro



## Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAVSGFTFN SFAMSWVRQA PGKGLEWVSA 50  
 ISGSGGGTTY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAKDK 100  
 ILWFGEVDFD YWCGQTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150  
 VKDYFPEPVT VSWNSGALTS GVHTFFAVLQ SSGLYSLSSV VTPVSSSLGT 200  
 QTYICNVNHH PSNTRVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250  
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300  
 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350  
 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTT 400  
 PVLDSDSGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTKQSLSLSP 450  
 GK 452

## Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50  
 ASNRRATGIPA RFGSGSGGTD FTLTISLSLEP EDFAVYYCQQ RSNWPPFTFGQ 100  
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150  
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200  
 LSSPVTKSFN RGEK 214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 266-326 372-430  
 22"-96" 149"-205" 266"-326" 372"-430"  
 Intra-L 23'-88" 134'-194"  
 23"'-88"' 134"'-194"  
 Inter-H-L 225-214" 225"-214"  
 Inter-H-H 231-231" 234-234"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

302, 302"

davalintidum #  
davalintide

## amylin analogue

human islet amyloid polypeptide-(1-7)-peptidyl-  
 [11-L-arginine(K>R), 18- L-arginine(K>R)]salmon  
 calcitonin-1 (*Oncorhynchus keta*)-(8-27)-peptidyl-human islet  
 amyloid polypeptide-(33-37)-peptidamide

## davalintide


## analogue de l'amyline

polypeptide amyloïde d'îlots pancréatiques humains-(1-7)-peptidyl-  
 [11-L-arginine(K>R), 18-L-arginine(K>R)]calcitonine-1 de saumon  
 (*Oncorhynchus keta*)-(8-27)-peptidyl-polypeptide amyloïde d'îlots  
 pancréatiques humains-(33-37)-peptidamide

## davalintida

## análogo de la amilina

polipéptido amiloide de los islotes pancreáticos humanos-(1-7)-  
 peptidil-[11-L-arginina(K>R), 18-L-arginina(K>R)]calcitonina-1 de  
 salmón (*Oncorhynchus keta*)-(8-27)-peptidil-polipéptido amiloide de  
 los islotes pancreáticos humanos -(33-37)-peptidamida



H-Lys—Cys—Asn—Thr—Ala—Thr—Cys—Val—Leu—Gly—Arg—Leu—  
 Ser—Gln—Glu—Leu—His—Arg—Leu—Gln—Thr—Tyr—Pro—Arg—  
 Thr—Asn—Thr—Gly—Ser—Asn—Thr—Tyr—NH<sub>2</sub>

elinogrelum  
elinogrel


*N*-[(5-chlorothiophen-2-yl)sulfonyl]-*N'*-{4-[6-fluoro-7-(methylamino)-  
 2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phenyl}urea

## élinogrel

*N*-[(5-chlorothiophén-2-yl)sulfonyl]-*N'*-{4-[6-fluoro-7-(méthylamino)-  
 2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phényl}urée

elinogrel *N*-[(5-clorotiofen-2-il)sulfonil]-*N'*-{4-[6-fluoro-7-(metilamino)-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]fenil}urea

$C_{20}H_{15}ClF_5O_5S_2$



**elisidepsinun**  
elisidepsin

13,8-anhidro{*N*-[(4*S*)-4-metilhexanoyl]-*D*-valil-L-treonil-L-valil-*D*-valil-*D*-proyl-L-ornitil-*D*-alioisoleucil-*D*-allothreonyl-*D*-alioisoleucil-*D*-valil-L-fenilalanil-(2*Z*)-2-aminobut-2-enoyl-L-valine}


élisidepsine

13,8-anhidro{*N*-[(4*S*)-4-méthylhexanoyl]-*D*-valil-L-thréonyl-L-valil-*D*-valil-*D*-proyl-L-ornitil-*D*-alioisoleucil-*D*-allothréonyl-*D*-alioisoleucil-*D*-valil-L-phénylalanil-(2*Z*)-2-aminobut-2-énoyl-L-valine}

elisidepsina

13,8-anhidro{*N*-[(4*S*)-4-metilhexanoil]-*D*-valil-L-treonil-L-valil-*D*-valil-*D*-proil-L-ornitil-*D*-alioisoleucil-*D*-alotreonil-*D*-alioisoleucil-*D*-valil-L-fenilalanil-(2*Z*)-2-aminobut-2-enoyl-L-valina}

$C_{75}H_{124}N_{14}O_{16}$



**elpetriginum**  
elpetrigine



3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine

elpétrigine

3-(2,3,5-trichlorophényl)pyrazine-2,6-diamine

elpetrigina

3-(2,3,5-triclorofenil)pirazina-2,6-diamina

**enisamii iodidum**

enisamium iodide



iodure d'énisamium

ioduro de enisamio

4-(benzylcarbamoyl)-1-methylpyridin-1-ium iodide

iodure de 4-(benzylcarbamoyl)-1-méthylpyridinium

ioduro de 4-(benzilcarbamoil)-1-metilpiridin-1-io

**eptacogum alfa pegolum (activatum) #**

eptacog alfa pegol (activated)

eptacog alfa pégol (activé)

eptacog alfa pegol (activado)

pegylated human coagulation factor VII, activated blood-coagulation factor VII (EC 3.4.21.21, serum prothrombin conversion accelerator), human factor VII light chain (135-262)-disulfide with human factor VII heavy chain, some sialyl units of the *N*-linked carbohydrates are mono-*O*-[ $\alpha$ -methylpoly(oxyethylene) hydrogen phosphate] esterified (average value of the ratio factor VII/pegol is close to 1)

facteur VII humain de la coagulation pégylé, activé  
facteur VII de la coagulation sanguine (EC 3.4.21.21, accélérateur de conversion de la prothrombine sérique), (135-262) disulfure entre la chaîne légère et la chaîne lourde du facteur VII humain, quelques unités acide *N*-acétylneuraminique de la partie *N*-glycosyl sont estérifiées, mono-*O*-[ $\alpha$ -méthylpoly(oxyéthylène) hydrogénophosphate] (rapport facteur VII/pegol voisin de 1)

factor VII de coagulación humano pegilado, activado  
factor VII de coagulación sanguínea (EC 3.4.21.21, acelerador de conversión de la protrombina de suero), (135-262) disulfuro entre la cadena ligera y la cadena pesada del factor VII humano, algunas unidades acido *N*-acetilneuraminico de la parte *N*-glicosilo están esterificadas, mono-*O*-[ $\alpha$ -metilpoli(oxietileno) hidrogenofosfato] (relación factor VII/pegol cercano de 1)

$C_{1982}H_{3054}N_{560}O_{618}S_{28}$ 

Light chain / Chaîne légère / Cadena ligera

ANAFLEELRP GSLEERCKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50  
 ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100  
 YCSDHGTGKR SCRCHEGYSL LADGVSCPTP VEYPCGKIPI LEKRNASKPQ 150  
 GR 152

Heavy chain / Chaîne lourde / Cadena pesada


IVGGKVCP KGECPWQVLL LVNGAQLCGG TLINTIWWVS AAHCFDKIKN 200  
 WRNLI AVLGE HDLSEHDGDE QSRRAQVVI PSTYVPGTTN HDIALLRLHQ 250  
 PVVLTDPHVP LCLPERTFSE RTLAFVRFSL VSGWGQLDR GATALELMVL 300  
 NVPRLMTQDC LQQRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT 350  
 HYRGTWYLTG IVSWGQGCAT VGHFVGYTRV SQYIENLQKL MRSEPRPGVL 400  
 LRAPFF 406

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

17-22 50-61 55-70 72-81 91-102 98-112  
 114-127 135-262 159-164 178-194 310-329 340-368

Modified residues / Résidus modifiés / Residuos modificados

E  
 6-7-14-16-19-20-25-26-29-35  
 4-carboxyGlu



Glycosylation sites (S, N) / Sites de glycosylation (S, N) / Posiciones de glicosilación (S, N)

Ser-52 Ser-60 Asn-145 Asn-322

 $(\beta\text{-Xyl})_n\text{-}\beta\text{-Glc}\rightarrow\text{S-52}$   $\alpha\text{-Fuc}\rightarrow\text{S-60}$  $n = 0-2$  $\text{R}\rightarrow\text{3-}\beta\text{-Gal}\rightarrow\text{3-}\beta\text{-Gl-N}\rightarrow\text{2-}\alpha\text{-Man}\rightarrow\text{6-}$  $\text{R}'\rightarrow\text{3-}\beta\text{-Gal}\rightarrow\text{3-}\beta\text{-Gl-N}\rightarrow\text{2-}\alpha\text{-Man}\rightarrow\text{3-}$  }  $\beta\text{-Man}\rightarrow\text{4-}\beta\text{-Gl-N}\rightarrow\text{4-}\beta\text{-Gl-N}\rightarrow\text{N}$ R =  $\alpha\text{-Sia}$ , R' =  $\alpha\text{-Sia}$  or PEG- $\alpha\text{-Sia}$  or R' =  $\alpha\text{-Sia}$ , R =  $\alpha\text{-Sia}$  or PEG- $\alpha\text{-Sia}$ 

Fuc = 6-deoxy-L-galactopyranosyl

Gal = D-galactopyranosyl

Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl

Man = D-mannopyranosyl

PEG- = O-[ $\alpha$ -methylpoly(oxyethylene) hydrogen phosphate]Sia = 5-N-acetyl- $\alpha$ -neuramin-2-yl

Xyl = D-xylopyranosyl

**etamicastatum**

etamicastat


5-(2-aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1,3-dihydro-2H-imidazole-2-thione

étamicastat

5-(2-aminoéthyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1,3-dihydro-2H-imidazole-2-thione

etamicastat

5-(2-aminoetil)-1-[(3R)-6,8-difluoro-3,4-dihidro-2H-cromen-3-il]-1,3-dihidro-2H-imidazol-2-tiona

 $C_{14}H_{15}F_2N_3OS$ 

**evatanepagum**


evatanepag

2-{3-[(N-[[4-(*tert*-butyl)phenyl]methyl]pyridine-3-sulfonamido)methyl]phenoxy}acetic acid

évatanépag

acide 2-{3-[(N-[[4-(*tert*-butyl)phényl]méthyl]pyridine-3-sulfonamido)méthyl]phénoxy}acétique

evatanepag

ácido 2-{3-[(N-[[4-(*terc*-butil)fenil]metil]piridina-3-sulfonamido)metil]fenoxi}acéticoC<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S**fezakinumabum #**

fezakinumab


immunoglobulin G1-lambda, anti-[*Homo sapiens* interleukin 22 (IL22, IL-22, ILTIF, IL-TIF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; (230-230":233-233")-bisdisulfide dimer

fézakinumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* interleukine 22 (IL22, IL-22, ILTIF, IL-TIF)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dimère (230-230":233-233")-bisdisulfure

fezakinumab

inmunoglobulina G1-lambda, anti-[interleukina 22 (IL22, IL-22, ILTIF, IL-TIF) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dímero (230-230":233-233")-bisdisulfuro



## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYMHWVRQA PGQGLEWVGM 50  
 INPYTGSAFY AQKFRGRVTM TRDTSISTAY MELSLRSDD TAVYYCAREP 100  
 EKFDSDSDSV WGRGTLVTVS SASTKGPSVF PLAPSSKSTS GGTALGCLV 150  
 KDYFPEPVTV SWNSGALTSV VHTFPAVLQS SGLYSLSSV TVPSSSLGTQ 200  
 TYICNVNHKP SNTKVDKQVE PKSCDKTHTC PFCPEPELLG GPSVFLFPPK 250  
 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300  
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350  
 QVYTLPPSRE EMTKNQVSLT CLVKGFPYPSD IAVEWESNGQ PENNYKTTTP 400  
 VLDSDGSEFFL YSKLTVDKSR WQQGNVFSQS VMHEALHNYH TQKSLSLSPG 450

## Light chain / Chaîne légère / Cadena ligera

QAVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYGVHWYQQ LPGTAPKLLI 50  
 YGDSNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDNSLSGY 100  
 VFGGGTQLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYFGAVT 150  
 VAWKADSSPV KAGVETTPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200  
 THEGSTVEKT VAPTECS 217

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 148-204 265-325 371-429  
 22"-96" 148"-204" 265"-325" 371"-429"  
 Intra-L 22'-90' 139'-198'  
 22'''-90''' 139'''-198'''  
 Inter-H-L 224-216' 224"-216"  
 Inter-H-H 230-230" 233-233"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

301, 301"

**filibuvirum**

filibuvir



(6*R*)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-  
 3-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-  
 5,6-dihydro-2*H*-pyran-2-one

filibuvir

(6*R*)-6-cyclopentyl-6-[2-(2,6-diéthylpyridin-4-yl)éthyl]-  
 3-[(5,7-diméthyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)méthyl]-4-hydroxy-  
 5,6-dihydro-2*H*-pyran-2-one

filibuvir

(6*R*)-6-ciclopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-  
 3-[(5,7-dimetil[1,2,4]triazolo[1,5-*a*]pirimidin-2-il)metil]-4-hidroxi-  
 5,6-dihidro-2*H*-piran-2-ona

**flutemetamol (<sup>18</sup>F)**

flutemetamol (<sup>18</sup>F)



2-{3-[<sup>18</sup>F]fluoro-4-(methylamino)phenyl}-1,3-benzothiazol-6-ol

flutémétamol (<sup>18</sup>F)

2-[3-[<sup>18</sup>F]fluoro-4-(méthylamino)phényl]-1,3-benzothiazol-6-ol

flutemetamol (<sup>18</sup>F)

2-{3-[<sup>18</sup>F]fluoro-4-(metilamino)fenil}-1,3-benzotiazol-6-ol



**fonturacetamum**


fonturacetam

*rac*-2-[(4*R*)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide

fonturacétam

*rac*-2-[(4*R*)-2-oxo-4-phénylpyrrolidin-1-yl]acétamide

fonturacetam

*rac*-2-[(4*R*)-4-fenil-2-oxopirrolidin-1-il]acetamidC<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>**fresolimumabum #**

fresolimumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* transforming growth factor beta (TGFB or TGFbeta or TGF-beta, including TGF-beta-1 or TGFB1, TGF-beta-2 or TGFB2 or G-TsF and TGF-beta-3 or TGFB3)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; (226-226":229-229")-bisdisulfide dimer

frésolimumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* facteur de croissance transformant bêta (TGFB ou TGFbêta ou TGF-bêta, comprenant TGF-bêta1 ou TGFB1, TGF-bêta2 ou TGFB2 ou G-TsF et TGF-bêta3 ou TGFB3)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimère (226-226":229-229")-bisdisulfure

fresolimumab

inmunoglobulina G4-kappa, anti-[factor de crecimiento transformador beta de *Homo sapiens* (TGFB o TGFbeta o TGF-beta, incluye TGF-beta-1 o TGFB1, TGF-beta-2 o TGFB2 o G-TsF y TGF-beta-3 o TGFB3)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dímero (226-226":229-229")-bisdisulfuro



C<sub>6392</sub>H<sub>9926</sub>N<sub>1698</sub>O<sub>2026</sub>S<sub>44</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SCKASGYTFS SNVISWVRQA PGQGLEWMGG 50  
 VIPIVDIANY AQRFKGRVTI TADESTSTTY MELSSLRSED TAVYYCASTL 100  
 GLVLDAMDYV GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150  
 DYFPEPVTVS WNSGALTSKV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200  
 YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPPKPKDT 250  
 LMISRTPEVT CVVVDVSDQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300  
 RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350  
 LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVVLDL 400  
 DGSFFLYSRL TVDKSRWQEG NVFSCSVME ALHNHYTQKS LSLSLGK 447

## Light chain / Chaîne légère / Cadena ligera

ETVLTQSPGT LSLSPGERAT LSCRASQSLG SSYLAWYQQK PGQAPRLLIY 50  
 GASSRAPGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYADSPITFG 100  
 QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150  
 VDNALQSGNS QESVTEQDSK DSTYLSLSTL TLSKADYEKH KVAACEVTHQ 200  
 GLSSPVTKSF NRGEK 215

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 147-203 261-321 367-425  
 22"-96" 147"-203" 261"-321" 367"-425"

Intra-L 23'-89' 135'-195'  
 23"-89" 135"-195"

Inter-H-L 134-215' 134"-215"  
 Inter-H-H 226-226" 229-229"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

**girentuximabum #**  
girentuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* carbonic anhydrase IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody; gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

## girentuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* anhydrase carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

## girentuximab

inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de *Homo sapiens* (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

C<sub>6460</sub>H<sub>10006</sub>N<sub>1718</sub>O<sub>2018</sub>S<sub>48</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

DVKLVESGGG LVKLGGSLLK SCAASGFTFS NYMSWVRQT PEKRLELVAA 50  
 INSDGGITYY LDTVKGRFTI SRDNAKNTLY LQMSSLKSED TALFYCARHR 100  
 SGYFMSDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150  
 YFPEPVTVSW NSGALTSQVH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200  
 ICNVNHPSPN TKVDKKEVEK SCDKTHTCP CPAPPELLGGP SVFLFPKPK 250  
 DTLMISRPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300  
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350  
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVV 400  
 DSDGSFFLYS KLTVDKSRWQ QGNVFCSCVM HEALHNHYTQ KSLSLSPGK 449

## Light chain / Chaîne légère / Cadena ligera

DIVMTQSQRF MSTTVGDRVS ITCKASQNVV SAVAWYQKP GQSPKLLIYS 50  
 ASNRYTQVPD RFTGSGSGTD FTLTISNMQS EDLADFFCQQ YSNYPWTFGG 100  
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150  
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200  
 LSSPVTKSFN RGEK 214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427  
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L 23'-88' 134'-194'  
 23'''-88''' 134'''-194'''

Inter-H-L 222-214' 222"-214"  
 Inter-H-H 228-228" 231-231"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

**gisadenafilum**

gisadenafil


5-[2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

gisadénafil

5-[2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]pyridin-3-yl]-3-éthyl-2-(2-méthoxyéthyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

gisadenafilo

3-etil-5-[5-[(4-etilpiperazin-1-il)sulfonyl]-2-etoxipiridin-3-il]-2-(2-metoxietil)-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona

C<sub>23</sub>H<sub>33</sub>N<sub>7</sub>O<sub>5</sub>S**givinostatium**

givinostat



{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate

givinostat

[4-(hydroxycarbamoyl)phényl]carbamate de {6-[(diéthylamino)méthyl]naphtalén-2-yl}méthyle

givinostat

[4-(hidroxicarbamoil)fenil]carbamato de {6-[(dietilamino)metil]naftalen-2-il}metilo

**golnerminogenum pradenovecum #**

golnerminogene pradenovec

a replication deficient human adenovirus 5 viral vector deleted in the E1, E4 and part of the E3 region and expressing a human tumour necrosis factor alpha (TNF- $\alpha$ ) gene inserted in the E1 region and under the control of an Egr-1 promoter and the SV40 polyadenylation sequence

golnerminogène pradénovec

vecteur viral adénovirus humain 5 sans capacité de réplication, dont les régions E1, E4 et une partie de la région E3 ont été supprimées, et exprimant un gène humain du facteur de nécrose tumorale alpha (TNF- $\alpha$ ) inséré dans la région E1 et sous le contrôle d'un promoteur Egr-1 et la séquence de polyadénylation SV40

golnerminogén pradenovec

vector viral adenovirus humano 5 sin capacidad de replicación con delección de E1, E4 y parte de la región E3 y que expresa un gen humano del factor de necrosis tumoral alfa (TNF- $\alpha$ ) insertado en la región E1 y bajo control de un promotor Egr-1 y la secuencia de poliadenilación de SV40

**gosogliptinum**

gosogliptin



(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone

gosogliptine

(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}méthanone

gosogliptina

(3,3-difluoropirrolidin-1-il){(2S,4S)-4-[4-(pirimidin-2-il)piperazin-1-il]pirrolidin-2-il}metanona

**imagabalinum**

imagabalin



(3S,5R)-3-amino-5-methyloctanoic acid

imagabaline

acide (3S,5R)-3-amino-5-méthyloctanoïque

imagabalina

ácido (3S,5R)-3-amino-5-metiloctanoico



**imételstatum**

imételstat


3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanylyl-(3'→5')-3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thiocytidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxyadenosine 5'-(*O*-[2-hydroxy-3-(hexadecanoylamino)propyl] hydrogen phosphorothioate)

imételstat

5'-(*O*-[2-hydroxy-3-(hexadécanoylamino)propyl] hydrogénophosphorothioate) de 3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioguanylyl-(3'→5')-3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioguanylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thiocytidylyl-(3'→5')-3'-amino-2',3'-didéoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-didéoxyadénosine

imételstat

5'-(*O*-[2-hidroxi-3-(hexadecanoilamino)propil] hidrógenofosforotioato) de 3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tiocitidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxiadenosina

C<sub>148</sub>H<sub>211</sub>N<sub>68</sub>O<sub>53</sub>P<sub>13</sub>S<sub>13</sub>(3'→5')d(3'-amino-3'-deoxy-*P*-thio)(-pT-A-G-G-G-T-T-A-G-A-C-A-A)**insulinum degludecum**

insulin degludec


*N*<sup>6</sup>.B<sub>29</sub>-[*N*<sup>2</sup>-(15-carboxypentadecanoyl)-L-γ-glutamyl]-des-B30-L-threonine-insulin human

insuline dégludec

*N*<sup>6</sup>.B<sub>29</sub>-[*N*<sup>2</sup>-(15-carboxypentadécanoyl)-L-γ-glutamyl]-dés-B30-L-thréonine-insuline humaine

insulina degludec

*N*<sup>6</sup>.B<sub>29</sub>-[*N*<sup>2</sup>-(15-carboxipentadecanoil)-L-γ-glutamyl]-des-B30-L-treonina-insulina humana

C<sub>274</sub>H<sub>411</sub>N<sub>65</sub>O<sub>81</sub>S<sub>6</sub>

**intetumumabum #**

intetumumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* integrin alpha-V (CD51, ITGAV, subunit of alphaV-beta3 or CD51/CD61 or vitronectin receptor or VNR, subunit of alphaV-beta5)], *Homo sapiens* monoclonal antibody;  
 gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

intétumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* intégrine alpha-V (CD51, ITGAV, sous-unité de alphaV-bêta3 ou CD51/CD61 ou récepteur de la vitronectine ou VNR, sous-unité de alphaV-bêta5)], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

intetumumab

inmunoglobulina G1-kappa, anti-[integrina alfa-V de *Homo sapiens* (CD51, ITGAV, subunidad de alfaV-beta3 o CD51/CD61 o receptor de la vitronectina o VNR, subunidad de alfaV-beta5)], anticuerpo monoclonal de *Homo sapiens*;  
 cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro

C<sub>6468</sub>H<sub>10008</sub>N<sub>1744</sub>O<sub>2006</sub>S<sub>40</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGRSRRL SCAASGFTFS RYTMHWVRQA PGKGLEWVAV 50  
 ISFDGSKYY VDSVKGRFTI SRDENSENTLY LQVNLRAED TAVYYCAREA 100  
 RGSYAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150  
 YFPEPVTWSW NSGALTSQSVH TFFPAVLQSSG LYSLSVVTV PSSSLGTQTY 200  
 ICNVNHKPSN TKVDKVEPK SCDKTHCTCP CPAPPELLGGP SVFLFPPKPK 250  
 DTLNISRTEPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300  
 TYRVSVLTFL LHQDNLNGKE YKCKVSNKAL PAPIEKTISK ARGQPREPOV 350  
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVVL 400  
 DSDGSFFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

## Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50  
 ASNRATGIPA RFGSGSGSTD FTLTISSELP EDFAVYYCQQ RSNWPPFTFG 100  
 PGTQVDIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNMF YPREAKVQWK 150  
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYEKH KVAACEVTHQ 200  
 GLSSPVTKSF NRGEC 215

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427  
 22"-96" 146"-202" 263"-323" 369"-427"  
 Intra-L 23'-88' 135'-195'  
 23'''-88''' 135'''-195'''  
 Inter-H-L 222-215' 222"-215"  
 Inter-H-H 228-228" 231-231"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

**iodum (<sup>124</sup>I) girentuximabum #**  
 iodine (<sup>124</sup>I) girentuximab


immunoglobulin G1-kappa, anti-[*Homo sapiens* carbonic anhydrase IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody radiolabeled with iodine-124;  
 gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; (228-228'':231-231'')-bisdisulfide dimer covalently linked to iodine-124

iodine (<sup>124</sup>I) girentuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* anhydrase carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal chimérique marqué à l'iode 124;  
 chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure lié de façon covalente à de l'iode 124

iodine (<sup>124</sup>I) girentuximab

inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de *Homo sapiens* (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico marcado con iodo 124;  
 cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro covalentemente ligado con iodo 124



Heavy chain / Chaîne lourde / Cadena pesada

DVKLVESGGG	LVKLGGSLKL	SCAASGFTFS	NYMSWVRQT	PEKRELVA	50
INSDGGITYY	LDTVKGRFTI	SRDNAKNTLY	LQMSSLKSED	TALFYCARHR	100
SGYFSDMYWG	QGTSTVTSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTWSW	NSGALTSQVH	TFFAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHPSPN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPKPK	250
DTLMISRTP	ETCIVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDMLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVPL	400
DSDGSEFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DIVMTQSQR	FSTTVGDRVS	ITCKASQNVV	SAVAWYQQK	GPSPKLLIYS	50
ASNRYTGVDP	RFTGSGSGTD	FLLTISNMQS	EDLADFFCQQ	YSNYPTWFGG	100
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWVK	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-88"	134'-194"		
	23'''-88'''	134'''-194'''		
Inter-H-L	222-214'	222"-214'"		
Inter-H-H	228-228"	231-231"		


N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
 299, 299"

**isopropylis tufofexoras**  
tufofexorate isopropylpropan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-*b*]indole-5-carboxylate

isopropyl de tufofexorate

3-(3,4-difluorobenzoyl)-1,1-diméthyl-1,2,3,6-tétrahydroazépino[4,5-*b*]indole-5-carboxylate de propan-2-yle

tufofexorato de isopropilo

3-(3,4-difluorobenzoi)-1,1-dimetil-1,2,3,6-tetrahydroazepino[4,5-*b*]indol-5-carboxilato de propan-2-iloC<sub>25</sub>H<sub>24</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>**lagociclovirum**


lagociclovir

2-amino-9-(2,3-dideoxy-3-fluoro-β-D-erythro-pentofuranosyl)-1,9-dihydro-6*H*-purin-6-on

lagociclovir

2-amino-9-(2,3-didéoxy-3-fluoro-β-D-érythro-pentofuranosyl)-1,9-dihydro-6*H*-purin-6-one

lagociclovir

2-amino-9-(2,3-didesoxi-3-fluoro-β-D-eritro-pentofuranosil)-1,9-dihidro-6*H*-purin-6-onaC<sub>10</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>3</sub>**lebrikizumabum #**

lebrikizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* interleukin 13 (IL13, IL-13)], humanized monoclonal antibody; gamma4 heavy chain [humanized VH (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 hinge S10>P (119-445)], (132-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; (224-224'':227-227'')-bisdisulfide dimer

lébrikizumab immunoglobuline G4-kappa, anti-[*Homo sapiens* interleukine 13 (IL13, IL-13)], anticorps monoclonal humanisé; chaîne lourde gamma4 [VH humanisé (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 charnière S10>P (119-445)], (132-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dimère (224-224":227-227")-bisdisulfure

lebrikizumab inmunoglobulina G4-kappa, anti-[interleukina 13 de *Homo sapiens* (IL13, IL-13)], anticuerpo monoclonal humanizado; cadena pesada gamma4 [VH humanizada (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 bisagra S10>P (119-445)], (132-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dímero (224-224":227-227")-bisdisulfuro

C<sub>6434</sub>H<sub>9972</sub>N<sub>1700</sub>O<sub>2034</sub>S<sub>50</sub>

Heavy chain / Chaîne lourde / Cadena pesada

QVTLRESGPA	LVKPTQTLTL	TCTVSGFSL	AYSVNWIRQP	PGKALEWLAM	50
INGDGKIVYN	SALKSRLTIS	KDTSKNQVVL	TMTNMDPVD	ATYYCAGDGY	100
YPYAMDNWQ	GSLVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPPEVTVSWN	SGALTSQVHT	FPAVLQSSGL	YSLSSVTVTF	SSSLGKTKYT	200
CNVDHKPSNT	KVDKRVESKY	GPPCPPCPAP	EFLGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSEQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTYRV	300
VSVLTVLHQD	WLNKKEYKCK	VSNKGLPSSI	EKTISKAKGQ	PREPQVYTL	350
PSQEEMTKNQ	VSLTCLVKG	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	400
SFFLYSRLTV	DKSRWQEGNV	FSCVMHEAL	HNHYTQKSL	LSLGLK	445

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS	LSVSLGERAT	INCRASKSVD	SYGNSFMHWY	QQKPGQPKL	50
LIYLASNLES	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCOQNNEDPR	100
TFGGGKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150
QWKVDNALQS	GNSQESVTEQ	DSKDYSTYLS	STLTLSKADY	EKHRYACEV	200
THQGLSSPVT	KSFNRGEC				218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95"	145-201"	259-319"	365-423"
	22"-95"	145"-201"	259"-319"	365"-423"
Intra-L	23'-92'	138'-198'		
	23"'-92'"	138"'-198'"		
Inter-H-L	132-218"	132"-218"		
Inter-H-H	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

295, 295"


lersivirinum

lersivirine 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzene-1,3-dicarbonitrile

lersivirine 5-[[3,5-diéthyl-1-(2-hydroxyéthyl)-1H-pyrazol-4-yl]oxy]benzène-1,3-dicarbonitrile

lersivirina 5-[[3,5-dietil-1-(2-hidroxietil)-1H-pirazol-4-il]oxi]benceno-1,3-dicarbonitrilo

C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>





**levomequitazinum**


levomequitazine

10-[[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]méthyl]-10*H*-phénothiazine

lévoméquitazine

10-[[[2-(3*S*)-1-azabicyclo[2.2.2]oct-3-yl]méthyl]-10*H*-phénothiazine

levomequitazina

10-[[[(3*S*)-1-azabicyclo[2.2.2]octan-3-il]metil]-10*H*-fenotiazinaC<sub>20</sub>H<sub>22</sub>N<sub>2</sub>S**litronesibum**


litronesib

(-)-*N*-{4-(2,2-diméthylpropanoyl)-5-[[2-(éthylamino)éthanesulfonamido]méthyl]-5-phényl-4,5-dihydro-1,3,4-thiadiazol-2-yl}-2,2-diméthylpropanamide

litronésib

(-)-*N*-{4-(2,2-diméthylpropanoyl)-5-[[2-(éthylamino)éthanesulfonamido]méthyl]-5-phényl-4,5-dihydro-1,3,4-thiadiazol-2-yl}-2,2-diméthylpropanamide

litronesib

(-)-*N*-{4-(2,2-diméthylpropanoïl)-5-[[2-(éthylamino)éтаносulfonamido]metil]-5-fenil-4,5-dihydro-1,3,4-tiadiazol-2-il}-2,2-diméthylpropanamidaC<sub>23</sub>H<sub>37</sub>N<sub>5</sub>O<sub>4</sub>S<sub>2</sub>

or enantiomer  
(-)-isomer  
ou énantiomère  
(-)-isomère  
o enantiómero  
(-)-isómero

**lomitapidum**


lomitapide

*N*-(2,2,2-trifluoroéthyl)-9-(4-{4-[4'-(trifluorométhyl)][1,1'-biphényl]-2-carboxamido]piperidin-1-yl}butyl)-9*H*-fluorene-9-carboxamide

lomitapide

*N*-(2,2,2-trifluoroéthyl)-9-(4-{4-[4'-(trifluorométhyl)][1,1'-biphényl]-2-carboxamido]pipéridin-1-yl}butyl)-9*H*-fluorène-9-carboxamide

lomitapida

*N*-(2,2,2-trifluoroetil)-9-(4-{4-[4'-(trifluorometil)][1,1'-bifenil]-2-carboxamido]piperidin-1-il}butil)-9*H*-fluoreno-9-carboxamidaC<sub>39</sub>H<sub>37</sub>F<sub>6</sub>N<sub>3</sub>O<sub>2</sub>

**losmapimodum**


losmapimod

6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-  
*N*-(2,2-dimethylpropyl)pyridine-3-carboxamide

losmapimod

6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-méthylphényl]-  
*N*-(2,2-diméthylpropyl)pyridine-3-carboxamide

losmapimod

6-[5-(ciclopropilcarbamoil)-3-fluoro-2-metilfenil]-  
*N*-(2,2-dimetilpropil)piridina-3-carboxamidaC<sub>22</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>2</sub>**miravirsenum**

miravirsén


*all-P-ambo*-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-  
deoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioadenylyl-  
(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-  
methylene-*P*-thioguanilyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-  
*P*-thiouridylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-  
*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-  
(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-  
methylene-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-5-methyl-  
2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-  
methylene-*P*-thiocytidine

miravirsén


*all-P-ambo*-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-2'-  
déoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-méthylène-*P*-thioadénylyl-  
(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-  
méthylène-*P*-thioguanilyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-  
*P*-thiouridylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-  
*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-  
(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-  
méthylène-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-5-méthyl-  
2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-  
méthylène-*P*-thiocytidine

miravirsén

*todo-P-ambo*-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-  
desoxi-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-metileno-*P*-tioadenilil-(3'→5')-*P*-  
tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*,4'-*C*-metileno-  
*P*-tioguanilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-2'-  
desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-metil-2'-  
*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-  
metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-5-  
metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-5-metil-2'-*O*,4'-*C*-  
metileno-*P*-tiocitidina



(3'-5')(P-thio)(mC-dC-A-dT-dT-G-I-dC-dA-mC-dA-mC-dT-mC-mC)

**mocetinostatum**

mocetinostat



*N*-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide

mocétinostat

*N*-(2-aminophényl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}méthyl)benzamide

mocetinostat

*N*-(2-aminofenil)-4-({[4-(piridin-3-il)pirimidin-2-il]amino}metil)benzamida

**modithromycinum**

modithromycin


*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-ethyl-2-hydroxy-2,6,8,10,16,18-tétraméthyl-5,7-dioxo-13-{{[6-(1*H*-pyrazol-1-yl)pyridin-3-yl]méthoxyimino}-9-{{[3,4,6-tridéoxy-3-(diméthylamino)-β-*D*-xylohexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadecane-17-ylidène]acétamide

modithromycine

*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-éthyl-2-hydroxy-2,6,8,10,16,18-tétraméthyl-5,7-dioxo-13-({[6-(1*H*-pyrazol-1-yl)pyridin-3-yl]méthoxyimino)-9-{{[3,4,6-tridéoxy-3-(diméthylamino)-β-*D*-xylohexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadéc-17-ylidène]acétamide

moditromicina

*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-etil-2-hidroxi-2,6,8,10,16,18-hexametil-5,7-dioxo-13-{{[6-(1*H*-pirazol-1-il)piridin-3-il]metoxiimino}-9-{{[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi}-4,11,15-trioxabicyclo[8.5.4]nonadecane-17-ilidene]acetamido

C<sub>43</sub>H<sub>64</sub>N<sub>6</sub>O<sub>11</sub>**naluzotanum**


naluzotan

*N*-(3-{4-[4-(1-cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide

naluzotan

*N*-(3-{4-[4-(1-cyclohexylméthanesulfonamido)butyl]pipérazin-1-yl}phényl)acétamide

naluzotán

*N*-(3-{4-[4-(1-ciclohexilmetanosulfonamido)butil]piperazin-1-il}fenil)acetamidaC<sub>23</sub>H<sub>38</sub>N<sub>4</sub>O<sub>3</sub>S**nelotanserinum**


nelotanserin


1-[3-(4-bromo-1-methyl-1*H*-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea



nélotansérine

1-[3-(4-bromo-1-méthyl-1*H*-pyrazol-5-yl)-4-méthoxyphényl]-3-(2,4-difluorophényl)urée

nelotanserina

1-[3-(4-bromo-1-metil-1*H*-pirazol-5-il)-4-metoxifenil]-3-(2,4-difluorofenil)ureaC<sub>18</sub>H<sub>15</sub>BrF<sub>2</sub>N<sub>4</sub>O<sub>2</sub>

<b>ocriplasminum #</b>	
ocriplasmin	truncated human plasmin: human plasmin heavy chain A-(543-561)-peptide (548-666;558-566)- bisdisulfide with human plasmin light chain B
ocriplasmine	plasmine humaine tronquée : chaîne lourde A de la plasmine humaine-(543-561)-peptide (548- 666;558-566)-bisdisulfure avec la chaîne légère B de la plasmine humaine
ocriplasmina	plasma humana truncada: cadena pesada A de la plasma humana-(543-561)-péptido (548- 666;558-566)-bisdisulfuro con la cadena ligera B de la plasma humana
	$C_{1214}H_{1890}N_{338}O_{348}S_{14}$
	Truncated heavy chain / Chaîne lourde tronquée/ Cadena pesada truncada
	PQVEPKKCPG R APSFDCGK 550 561
	Light chain / Chaîne légère / Cadena ligera
	VVGGCVVAFP HSWPQVSLR TRFGMHFCGG TLISPEWVLT 600 AAHCLEKSPR PSSYKVI LGA HQEVNLEPHV QEIEVSRFLF EPTRKDIALL 650 KLSSPAVITD KVIPACLPSF NYVVADRTEC FITGWGETQG TFGAGLLKEA 700 QLPVIENKVC NRYEFLNGRV QSTELCAGHL AGGTDSCQGD SGGPLVCFEK 750 DKYILQGVTS WGLGCARPKNK PGVYVRVSRF VTWIEGVMRN N 791
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 548-666 558-566 588-604 680-747 710-726 737-765
<b>olodaterolum</b>	
olodaterol	6-hydroxy-8-[(1 <i>R</i> )-1-hydroxy-2-[[1-(4-methoxyphenyl)- 1,1-diméthyléthyl]amino]éthyl]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-one
olodatérol	6-hydroxy-8-[(1 <i>R</i> )-1-hydroxy-2-[[2-(4-méthoxyphényl)- 1,1-diméthyléthyl]amino]éthyl]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-one
olodaterol	6-hidroxi-8-[(1 <i>R</i> )-1-hidroxi-2-[[1-(4-metoxifenil)-2-metilpropan- 2-il]amino]etil]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-ona
	$C_{21}H_{26}N_2O_5$
	
<b>razupenemum</b>	
razupenem	(4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-[(1 <i>R</i> )-1-hydroxyéthyl]-4-méthyl-3-({4-[(5 <i>S</i> )-5-méthyl- 2,5-dihydro-1 <i>H</i> -pyrrol-3-yl]-1,3-thiazol-2-yl}sulfanyl)-7-oxo- 1-azabicyclo[3.2.0]hept-2-ène-2-carboxylic acid
razupénem	acide (4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-[(1 <i>R</i> )-1-hydroxyéthyl]-4-méthyl-3-({4-[(5 <i>S</i> )- 5-méthyl-2,5-dihydro-1 <i>H</i> -pyrrol-3-yl]thiazol-2-yl}sulfanyl)-7-oxo- 1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique
razupenem	ácido (4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-[(1 <i>R</i> )-1-hidroxietil]-4-metil-3-({4-[(5 <i>S</i> )-5-metil- 2,5-dihidro-1 <i>H</i> -pirrol-3-il]-1,3-tiazol-2-il}sulfanil)-7-oxo- 1-azabicyclo[3.2.0]hept-2-eno-2-carboxílico

**ridaforolimusum**

ridaforolimus



(1*R*,2*R*,4*S*)-4-[(2*R*)-2-  
 {(3*S*,6*R*,7*E*,9*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-  
 9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexaméthyl-  
 1,5,11,28,29-pentaoxo-  
 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34  
 a-tétracosahydro-3*H*-23,27-époxy-pyrido[2,1-  
 c][1,4]oxaazacyclohentricosin-3-yl}propyl]-2-méthoxycyclohexyl  
 diméthylphosphinate

ridaforolimus

(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)  
 -12-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-[(diméthylphosphinoyl)oxy]-  
 3-méthoxycyclohexyl]-1-méthyléthyl]-1,18-dihydroxy-  
 19,30-diméthoxy-15,17,21,23,29,35-hexaméthyl-11,36-dioxa-  
 4-azatricyclo[30.3.1.0<sup>4,9</sup>]hexatriaconta-16,24,26,28-tétrène-  
 2,3,10,14,20-pentone

ridaforolimus

(1*R*,2*R*,4*S*)-4-[(2*R*)-2-  
 {(3*S*,6*R*,7*E*,9*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-  
 9,27-dihydroxi-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-  
 1,5,11,28,29-pentaoxo-  
 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34  
 a-tétracosahydro-3*H*-23,27-époxy-pirido[2,1-  
 c][1,4]oxaazacyclohentricosin-3-yl}propyl]-2-méthoxycyclohexyl  
 diméthylfosfinato



**rilotumumabum #**

rilotumumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* hepatocyte growth factor (HGF, scatter factor, SF, hepatopoietin A)], *Homo sapiens* monoclonal antibody;  
 gamma2 heavy chain (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (222-222":223-223":226-226":229-229")-tetradisulfide dimer

rilotumumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* facteur de croissance de l'hépatocyte (HGF, facteur dispersant, SF, hépatopoïétine A)], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma2 (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (222-222":223-223":226-226":229-229")-tétradisulfure

rilotumumab

inmunoglobulina G2-kappa, anti-[factor de crecimiento de hepatocitos de *Homo sapiens* (HGF, factor dispersante, SF, hepatopoyetina A)], anticuerpo monoclonal de *Homo sapiens* ;  
 cadena pesada gamma2 (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (222-222":223-223":226-226":229-229")-tetradisulfuro

C<sub>6464</sub>H<sub>9932</sub>N<sub>1708</sub>O<sub>2010</sub>S<sub>46</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLQESGPG LVPSETLSL TCTVSGGSIS IYVSWIRQP PGKGLEWIGY 50
VYYSGSTNYN PSLKSRVTIS VDTSKNQFSL KLNSTVAADT AVYICARGGY 100
DFWSGYFDYW GQGLTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSKV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVR KCCVECPFCP APPVAGPSVF LFPFKPKDTL 250
MISRTPPEVTC VVVDVSHEDP EVQFNWYVVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNGKLPAP IEKTIKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVRG FYPSDIAVEW ESNQGPENNY KTTTPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCVMHEA LHNHYTQKSL SLSPGK 446

```

## Light chain / Chaîne légère / Cadena ligera

```

EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYRQKP GQAPRLLIYG 50
ASTRATGIPA RFGSGSGSTE FTLTISLQSS EDFAVYYCQQ YINWPPITFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYEKH KYVACEVTHQ 200
GLSSPVTKSF NRGEK 215

```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-95 147-203 260-320 366-424
          22"-95" 147"-203" 260"-320" 366"-424"
Intra-L 23'-88' 135'-195'
          23"-88" 135"-195"
Inter-H-L 134-215' 134'-215"
Inter-H-H 222-222" 223-223" 226-226" 229-229"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
 296, 296<sup>a</sup>

**rontalizumabum #**

rontalizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* interferon alpha (IFN-alpha)], humanized monoclonal antibody;  
gamma1 heavy chain [humanized VH (*Homo sapiens* IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; (226-226":229-229")-bisdisulfide dimer

rontalizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* interféron alpha (IFN-alpha)], anticorps monoclonal humanisé;  
chaîne lourde gamma1 [VH humanisé (*Homo sapiens* IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure

rontalizumab

inmunoglobulina G1-kappa, anti-[interferón alfa de *Homo sapiens* (IFN-alpha)], anticuerpo monoclonal humanizado;  
cadena pesada gamma1 [VH humanizada (*Homo sapiens* IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro

C<sub>6486</sub>H<sub>9990</sub>N<sub>1722</sub>O<sub>2026</sub>S<sub>44</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCATSGYTFT EYIIHWVROA PGKGLEWVAS 50
INPDYDITNY NQRFKGRFTI SLDKSKRTAY LQMNSLRAED TAVYYCASWI 100
SDFFDYWGQG TLVTVSSAST KGPSVFPPLAP SSKSTSGGTA ALGCLVRYDF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHNKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTEPVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREPEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350
LPPSRREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPPVLD 400
DGSFFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LLSLSPGK 447
```

## Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCRASQSVS TSSYSYMHWY QOKPGKAPKV 50
LISYASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQHSWGIPIR 100
TFGQGTKEVI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLT STLTLKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 144-200 261-321 367-425
          22"-96" 144"-200" 261"-321" 367"-425"
Intra-L 23'-92' 138"-198"
          23"'-92"" 138"'-198""
Inter-H-L 220-218' 220"-218""
Inter-H-H 226-226" 229-229"
```

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297<sup>1</sup>**semaglutidum**

semaglutide

N<sup>6,26</sup>-{[18-[N-(17-carboxyheptadecanoyl)-L-γ-glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl]-[8-(2-amino-2-propanoic acid),34-L-arginine]human glucagon-like peptide 1(7-37)}


sémaglutide

N<sup>6,26</sup>-{[18-[N-(17-carboxyheptadécanoyle)-L-γ-glutamyle]-10-oxo-3,6,12,15-tétraoxa-9,18-diazaoctadécanoyle]-[8-(acide 2-amino-2-méthylpropanoïque),34-L-arginine]peptide 1(7-37) apparenté au glucagon humain (GLP-1(7-37))}



semaglutida

$N^{6,26}$ -{18-[*N*-(17-carboxiheptadecanoil)-L- $\gamma$ -glutamil]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoil]-[8-(ácido 2-amino-2-metilpropanoico),34-L-arginina]péptido 1(7-37) similar al glucagón tipo 1 humano

 $C_{187}H_{291}N_{45}O_{59}$ 
**serdemetanum**

serdemetan


*N*-[2-(1*H*-indol-3-yl)ethyl]-*N'*-(pyridin-4-yl)benzene-1,4-diamine

serdémétan

*N*-[2-(1*H*-indol-3-yl)éthyl]-*N'*-(pyridin-4-yl)benzène-1,4-diamine

serdemetán

*N*-[2-(1*H*-indol-3-il)etil]-*N'*-(piridin-4-il)bencono-1,4-diamina

 $C_{21}H_{20}N_4$ 
**setileutonum**

setileuton


4-(4-fluorophenyl)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl)amino)methyl]-2*H*-chromen-2-one

sétileuton


4-(4-fluorophényl)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl)amino)méthyl]-2*H*-chromèn-2-one

setileutón

4-(4-fluorofenil)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hidroxibutan-2-il]-1,3,4-oxadiazol-2-il)amino)metil]-2*H*-cromen-2-ona

 $C_{22}H_{17}F_4N_3O_4$ 


<b>sifalimumabum #</b> sifalimumab	immunoglobulin G1-kappa, anti-[ <i>Homo sapiens</i> interferon alpha (IFN-alpha)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-446) [ <i>Homo sapiens</i> VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1 R120>K (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [ <i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (225-225":228-228")-bisdisulfide dimer
sifalimumab	immunoglobuline G1-kappa, anti-[ <i>Homo sapiens</i> interféron alpha (IFN-alpha)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma 1 (1-446) [ <i>Homo sapiens</i> VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1 R120>K (117-446)], (219-215')-disulfure avec la chaîne légère kappa (1'-215') [ <i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (225-225":228-228")-bisdisulfure
sifalimumab	inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de <i>Homo sapiens</i> ], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-446) [ <i>Homo sapiens</i> VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1 R120>K (117-446)], (219-215')-disulfuro con la cadena ligera kappa (1'-215') [ <i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225-225":228-228")-bisdisulfuro
	<b>C<sub>6396</sub>H<sub>9922</sub>N<sub>1714</sub>O<sub>2008</sub>S<sub>42</sub></b>
	Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYSISWVRQA PGQGLEWMGW 50 ISVYNGNTNY AOKFQGRVTM TTDTSSTSTAY LELRSLRSD TAVVYCARDP 100 IAAGYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTA LGCLVKDYFP 150 EPVTVSWMNSG ALTSVHTFP AVLQSSGLYS LSSVTVVPS SLGQTYICN 200 VNHKPSNTKV DKKVEPKSCD KHTCPCPCA PELLGGPSVF LFPKPKDNL 250 MISRTPPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKF REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNAKALPAP IEKTIKSKARG QPREPQVYTL 350 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQQPENNY KTTTPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTKSL SLSPGK 446
	Light chain / Chaîne légère / Cadena ligera EIVLTQSPGT LSLSPGERAT LSCRASQSVS STYLAWYQK PGQAPRLLIY 50 GASSRATGIP DRFSGSGGT DFTLTISRLE PEDFAVYVYQ QYGSPPRTFG 100 QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNLF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYLSLSTL TSKADYEKH KVVACEVTHQ 200 GLSSPVTKSF NRGEC 215
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 143-199 260-320 366-424 22"-96" 143"-199" 260"-320" 366"-424" Intra-L 23"-89" 135"-195" 23"-89" 135"-195" Inter-H-L 219-215' 219"-215" Inter-H-H 225-225" 228-228"
	N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 296, 296 <sup>a</sup>
<b>sonedenosomum</b> sonedenoson	2-[2-(4-chlorophenyl)ethoxy]adenosine
sonédénoson	2-[2-(4-clorofénil)étoxy]-9-β-D-ribofuranosyl-9H-purin-6-amine
sonedenosón	2-[2-(4-clorofenil)etoxi]adenosina

$C_{18}H_{20}ClN_5O_5$ **sothrombomodulinum alfa #**

sothrombomodulin alfa

soluble mutated human thrombomodulin  
[388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-alanine(S>A)]human thrombomodulin (fetomodulin, CD141)-(4-490)-peptide, glycosylated

sothrombomoduline alfa

thrombomoduline humaine soluble mutée  
[388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-alanine(S>A)]thrombomoduline humaine (fetomoduline, CD141)-(4-490)-peptide, glycosylée

sotrombomodulina alfa

trombomodulina humana soluble mutada  
[388-leucina(M>L),456-glicina(R>G),457-glutamina(H>Q),474-alanina(S>A)]trombomodulina humana (fetomodulina, CD141)-(4-490)-péptido, glicosilado $C_{2181}H_{3278}N_{616}O_{706}S_{49}$ 

```

EPQPPGGSQCV  EHDCFALYPG  PATFLNASQI  CDGLRGHLMT  VRSSVAADVI  50
SLLLNGDGGV  GRRRLWIGLQ  LPPGCGDPKR  LGPLRGFQWV  TGDNNTSYSR  100
WARLDLNGAP  LCGPLCVAVS  AAATVPSEP  IWEEQQCEVK  ADGFLCFEHH  150
PATCRPLAVE  PAAAAAASI  TYGTPFAARG  ADFQALPVGS  SAAVAPLGLQ  200
LMCTAPPGAV  QHWAREAPG  AWDCSVENG  CEHACNAIPG  APRCQCPAGA  250
ALQADGRSCT  ASATQSCNDL  CEHFCVFNPD  QPGSYSCMCE  TGYRLAADQH  300
RCEDVDCCIL  EPSFPCQRCV  NTQGGFECHC  YPNYDLVDGE  CPEPVDPCFR  350
ANCEYQCQPL  NQTSYLCVCA  EGFAPIPHEP  HRCQLFCNQT  ACPADCDPNT  400
QASCECEPEY  ILDDGFICTD  IDECEGGGFC  SGVCHNLFGT  FECICGPDSA  450
LAGQIGTDCD  SGRVDGGDSG  AGEPPPSPTP  GSTLTPP  487

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
*Total 23 disulfide bridges in the molecule, so far only four disulfide bridge positions verified.*  
*23 ponts disulfure au total dans la molécule, pour le moment, seuls quatre ont été vérifiés.*  
*23 puentes disulfuro en el total en la molécula, por el momento, sólo cuatro han sido verificados.*  
 9-14 31-146 154-203 224-235

N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
 Asn-26 Asn-95 Asn-361 Asn-388

**tafamidisum**

tafamidis



2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

tafamidis

acide 2-(3,5-dichlorophényl)-1,3-benzoxazole-6-carboxylique

tafamidis

ácido 2-(3,5-diclorofenil)-1,3-benzoxazol-6-carboxílico

**taliglucerasum alfa #**  
taliglucerase alfa

L-glutamyl-L-phenylalanyl-[495(497)-L-histidine(R>H)]human glucosylceramidase (beta-glucocerebrosidase) peptide with L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-threonyl-L-methionine, glycosylated peptide 1-506

## taliglucérase alfa

L-glutamyl-L-phénylalanyl-[495(497)-L-histidine(R>H)]glucosylcéramidase humaine (bêta-glucocérébrosidase) peptide avec la L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-thréonyl-L-méthionine, peptide 1-506 glycosylé

## taliglucerasa alfa

L-glutamil-L-fenilalanil-[495(497)-L-histidina(R>H)]glucosilceramidasa humana (beta-glucocerebrosidasa) péptido con la L-aspartil-L-leucil-L-leucil-L-valil-L-aspartil-L-treonil-L-metionina, péptido 1-506 glicosilado




```

EFARPCIPKS FGYSSVVCVC NATYCDSFDP PTFPALGTF S RYESTRSGRR 50
MELSMGPIQA NHTGTGLLLT LQPEQKFQKV KFGGAMTDA AALNILALSP 100
PAQNLLKSY FSEEGIGYNI IRVPMASCF SIRTYYADT PDDFQLHNF S 150
LPEEDTKLKI PLIHRALQLA QRPVSLLASP WTSPTWLKTN GAVNGKGS LK 200
GQPGDIYHQT WARYFVKFLD AYAETHKLQFW AVTAENEPSA GLLSGYPFQC 250
LGFTPEHQRD FIARDLGPTL ANSTHNNVRL LMLDDQRLLL PHWAKVVLTD 300
PEAAKYVHGI AVHWYLDPLA PAKATLGETH RLFPNTMLFA SEACVGSKEW 350
EQSVRLGSWD RGMQYSHSII TNLLYHVVGW TDWNLALNPE GGPNWVRNEV 400
DSPIIVDITK DTFYKQPMFY HLGHFSKFIP EGSQRVGLVA SQKNLD DAVA 450
LMHPDGSAVV VVLNRSSKDV PLTIKDPAVG FLETISPGYS IHTYLWHRQD 500
LLVDTM 506

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
6-18 20-25

Glycosylation sites N / Sites de glycosylation N / Posiciones de glicosilación N  
Asn-21 Asn-61 Asn-148 Asn-272



Fuc = 6-deoxy-D-galactopyranosyl  
Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl  
Man = D-mannopyranosyl  
Xyl = D-xylopyranosyl

**tecarfarinum**  
tecarfarin


1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate

## técarfarine

4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)méthyl]benzoate de 1,1,1,3,3,3-hexafluoro-2-méthylpropan-2-yl

## tecarfarina

4-[(4-hidroxi-2-oxo-2H-cromen-3-il)metil]benzoato de 1,1,1,3,3,3-hexafluoro-2-metilpropan-2-ilo

C<sub>21</sub>H<sub>14</sub>F<sub>6</sub>O<sub>5</sub>

**teglarinadi chloridum**  
teglarinad chloride


4-({*N*'-[6-(4-chlorophenoxy)hexyl]}-*N*'-cyanocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecyl)pyridin-1-ium chloride

chlorure de téglarinad

chlorure de 4-({*N*'-[6-(4-chlorophénoxy)hexyl]}-*N*'-cyanocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadécyl)pyridin-1-ium

cloruro de teglarinad

cloruro de 4-({*N*'-[6-(4-clorofenoxi)hexil]}-*N*'-cianocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecil)piridin-1-io

C<sub>30</sub>H<sub>43</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>8</sub>

**teprotumumabum #**  
teprotumumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* insulin-like growth factor 1 receptor (IGF1R, IGF-1R, IGF-1 receptor, CD221)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (227-227'':230-230'')-bisdisulfide dimer

téprotumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* récepteur du facteur de croissance 1 analogue à l'insuline (IGF1R, IGF-1R, récepteur de l'IGF-1, CD221)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure

teprotumumab

immunoglobulina G1-kappa, anti-[receptor del factor de crecimiento insulínico tipo 1 de *Homo sapiens* (IGF1R, IGF-1R, receptor del GF-1, CD221)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro

C<sub>6476</sub>H<sub>10012</sub>N<sub>1748</sub>O<sub>2000</sub>S<sub>40</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVELVESGGG VVQPGRSQR L SCAASGFTFS SYGMHWVROA PGKGLEWVAI 50  
 IWFDGSSTYY ADSVRGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAREL 100  
 GRRYFDLNGR GTLVSVSSAS TKGFSVFPLA PSSKSTSGGT AALGCLVKDY 150  
 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200  
 CNVNHKPSNT KVDKKVEPKS CDKTHTCPFC PAPELLGGPS VFLFPPKPKD 250  
 TLMISRTPEV TCVVVDVSH E DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300  
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350  
 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTTPVLD 400  
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNYTQK SLSLSPGK 448

## Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GPAPRLLIYD 50  
 ASKRATGIPA RFSGSGSGTD FTLTISSELP EDFAVYCYQQ RSKWPPPTFG 100  
 QGKTKVESKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150  
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYERK KKYACEVTHQ 200  
 GLSSPVTKSF NRGEC 215

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426  
 22"-96" 145"-201" 262"-322" 368"-426"  
 Intra-L 23"-88" 135"-195"  
 23"-88" 135"-195"  
 Inter-H-L 221-215' 221"-215"  
 Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
298, 298"**tipapkinogenum sovaccineum #**  
tipapkinogene sovaccine

an attenuated recombinant vaccinia viral vector (derived from the Modified Virus Ankara clone 33.1, MVATG33.1) containing an approximately 168 kilobasepair DNA genome encoding itself, human interleukin-2 (IL-2) and mutated-forms of the Human Papilloma Virus 16 (HPV-16) E6 and E7 antigens

## tipapkinogène sovaccine

vecteur viral de la vaccine recombinant atténué (dérivé du virus modifié Ankara clone 33.1, MVATG33.1) contenant un génome ADN d'approximativement 168 kilopaires de bases se codifiant lui-même, l'interleukine 2 humaine (IL-2) et des formes mutées du papillomavirus humain 16 (HPV-16) et les antigènes E6 et E7

## tipapkinogén sovaccine


vector viral vaccinia recombinante atenuado (derivado del Virus Modificado Ankara clon 33.1, MVATG33.1) contiene un DNA genómico de aproximadamente 168 kilopares de bases que codifican el propio virus, interleukina-2 (IL-2) humana y formas mutadas del Virus del papiloma humano 16 (HPV-16) y los antígenos E6 y E7


**varfollitropinum alfa #**  
varfollitropin alfa

[alpha,83-L-asparagine;beta,55-L-asparagine,57-L-threonine]  
 follitropin alpha (human) modified human follicle-stimulating hormone:  
 heterodimer of [83-L-asparagine(H>N)]human glycoprotein hormones alpha chain (FSH-alpha) and [55-L-asparagine(E>N), 57-L-threonine(V>T)]human follitropin subunit beta (FSH-beta), glycosylated

## varfollitropine alfa

[alpha,83-L-asparagine;bêta,55-L-asparagine,57-L-thrèonine]  
 follitropine alpha (humaine) hormone stimulante du follicule de De Graaf humaine modifiée :  
 hétérodimère constitué de la [83-L-asparagine(H>N)]chaîne alpha de la glycoprotéine des hormones humaines (FSH-alpha) et de la [55-L-asparagine(E>N),57-L-thrèonine(V>T)]sous-unité bêta de la follitropine humaine (FSH-bêta) glycosylées

varfolitropina alfa	<p>[alfa,83-L-asparagina;beta,55-L-asparagina,57-L-treonina] folitropina alfa (humana) hormona estimulante del foliculo de De Graaf humana modificada :</p> <p>heterodimero constituido por la [83-L-asparagina(H&gt;N)]cadena alfa de la glicoproteina de las hormonas humanas (FSH-alfa) y de la [55- L-asparagina(E&gt;N),57-L-treonina(V&gt;T)]subunidad beta de la folitropina humana (FSH-beta) glicosiladas</p> <p><math>C_{971}H_{1511}N_{267}O_{306}S_{26}</math></p> <p>Alpha subunit / Sous-unité alpha / Subunidad alfa  APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSTRAYPTP LRSKKTMLVQ 50  KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACNCSTCYHH KS 92</p> <p>Beta subunit / Sous-unité bêta / Subunidad beta  NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'  CTFKNLTYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDS SDTCTVRGLG 100'  PSYCSFGEMK E 111'</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  7-31 10-60 28-82 32-84 59-87  3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'</p> <p>N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  Asn-7' Asn-24' Asn-55' Asn-52 Asn-78</p>
<b>velusetragum</b> velusetrag	<p><i>N</i>-{[(1<i>R</i>,3<i>r</i>,5<i>S</i>)-8-[(2<i>R</i>)-2-hydroxy-3-(<i>N</i>-methylmethanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide</p>
vélusétrag	<p><i>N</i>-{[(1<i>R</i>,3<i>r</i>,5<i>S</i>)-8-[(2<i>R</i>)-2-hydroxy-3-(<i>N</i>-méthylméthanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide</p>
velusetrag	<p><i>N</i>-{[(1<i>R</i>,3<i>r</i>,5<i>S</i>)-8-[(2<i>R</i>)-2-hidroxi-3-(<i>N</i>-metilmetanosulfonamido)propil]-8-azabicyclo[3.2.1]octan-3-il]-2-oxo-1-(propan-2-il)-1,2-dihidroquinolina-3-carboxamida</p> <p><math>C_{25}H_{36}N_4O_5S</math></p>  <p>The chemical structure shows a complex molecule consisting of a quinoline ring system fused to a bicyclic azabicyclo[3.2.1]octane system. The quinoline part has a methyl group on the nitrogen and a propanoic acid derivative at the 3-position. The bicyclic part has a hydroxyl group and a methylsulfonamide group attached to it.</p>
<b>zaurategrastum</b> zaurategrast	<p>(2<i>S</i>)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-[(2,7-naphthyridin-1-yl)amino]phenyl]propanoic acid</p>
zauratégrast	<p>acide (2<i>S</i>)-2-[(2-bromo-3-oxospiro[3.5]non-1-én-1-yl)amino]-3-[4-(2,7-naphtyridin-1-ylamino)phényl]propanoïque</p>
zaurategrast	<p>ácido (2<i>S</i>)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-il)amino]-3-[4-[(2,7-naftiridin-1-il)amino]fenil]propanoico</p>



- # Electronic structure available on Mednet: <http://mednet.who.int/>
- # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.